Discovery of isoxazolyl-based inhibitors of <i>Plasmodium falciparum</i> cGMP-dependent protein kinase

Abstract

(PfPKG) plays multiple roles in the life cycle of the parasite. As a result, this enzyme is a potential target for new antimalarial agents. Existing inhbitors, while potent and active in malaria models are not optimal. This communication describes initial optimization of a structurally distinct class of PfPKG inhibitors.